Aprogen’s ‘Remicade’ biosimilar break into KRW 1 trillion Japanese market

Published: 2017-09-29 16:27:00
Updated: 2017-09-29 13:49:57

A ‘Remicade’ biosimilar developed by Aprogen has made a stepping stone to enter the KRW 1 trillion Japanese market.

Aprogen(CEO Jae-Seop Kim), a biosimilar company, announced the company acquired approval of its Remicade biosimilar(Japanese code name: NI-071) developed by the company from the Mi...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.